J Capital Research · 2021 · Published 24 June 2021
Anne Stevenson-Yang argues that ChromaDex lifts its share price with distribution announcements that yield few sales, such as a Walmart deal announced twice in 2021 and a Nestle deal that brought $559,000 in two years, so insiders can sell.
J Capital's short report of 24 June 2021, by Anne Stevenson-Yang, argues that ChromaDex (CDXC), which sells one supplement, Tru Niagen, uses press releases to lift its shares long enough for insider sales. It links the company to Barry Honig, Phillip Frost and Michael Brauser, whom the SEC called 'micro-cap fraudsters'. CDXC announced the same Walmart distribution twice, in March and June 2021, and its shares rose 14% and 7%; earlier deals with GNC, CVS, BPI Sports and Nectar7 produced little or no sales. The Nestle deal of December 2018 lifted the shares 30% but brought $559,000 in licensing fees over two years. The report adds that the FDA and FTC warned CDXC about Covid-19 claims and that it has lost money every year since at least 2009.
The latest promote is a Walmart distribution deal, announced twice, in March and in June, for full effect.Show in the letter ›